Paragraph IV Patent Certifications

October 21, 2014

The PDF contains a list of drug products for which an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification. This list includes the name of the drug product, dosage form, strength (subject of Paragraph IV certification), reference listed drug (RLD), and the date on which the first substantially complete generic drug application was submitted to the Agency (on a prospective basis beginning 3/2/2004). The Agency will not disclose the identity of the applicant. This information will be updated twice a month and will be as current as the last update. This information should be used for reference only. The Agency will make every effort to ensure the accuracy of the information disclosed in this list. However, any discrepancies or disparities should be discussed with the Regulatory Support Branch at 240-276-8400, before making any decisions based on this information.

AlcaftadineOphthalmic Solution0.25%Lastacaft7/30/2014
Azelastine Hydrochloride and Fluticasone PropionateNasal Spray137 mcg/50 mcg per sprayDymista6/13/2014
ExenatideInjection250 mg/mL, 1.2 mL and 2.4 mL prefilled syringeByetta6/11/2014
ParoxetineCapsules7.5 mgBrisdelle4/7/2014
RibavirinFor Inhalation Solution6 gm/vialVirazole5/22/2014
TopiramateExtended-release Capsules25 mg, 50 mg, and 100 mgTrokendi XR5/12/2014

Paragraph IV Patent Certifications (PDF - 2.1MB)

Page Last Updated: 10/22/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.